Literature DB >> 24325346

Cellular and molecular mechanisms in cancer immune escape: a comprehensive review.

Alka Bhatia1, Yashwant Kumar.   

Abstract

Immune escape is the final phase of cancer immunoediting process wherein cancer modulates our immune system to escape from being destroyed by it. Many cellular and molecular events govern the cancer's evasion of host immune response. The tumor undergoes continuous remodeling at the genetic, epigenetic and metabolic level to acquire resistance to apoptosis. At the same time, it effectively modifies all the components of the host's immunome so as to escape from its antitumor effects. Moreover, it induces accumulation of suppressive cells like Treg and myeloid derived suppressor cells and factors which also enable it to elude the immune system. Recent research in this area helps in defining the role of newer players like miRNAs and exosomes in immune escape. The immunotherapeutic approaches developed to target the escape phase appear quite promising; however, the quest for a perfect therapeutic agent that can achieve maximum cure with minimal toxicity continues.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24325346     DOI: 10.1586/1744666X.2014.865519

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  39 in total

Review 1.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

2.  Integrated molecular analysis of adult T cell leukemia/lymphoma.

Authors:  Keisuke Kataoka; Yasunobu Nagata; Akira Kitanaka; Yuichi Shiraishi; Teppei Shimamura; Jun-Ichirou Yasunaga; Yasushi Totoki; Kenichi Chiba; Aiko Sato-Otsubo; Genta Nagae; Ryohei Ishii; Satsuki Muto; Shinichi Kotani; Yosaku Watatani; June Takeda; Masashi Sanada; Hiroko Tanaka; Hiromichi Suzuki; Yusuke Sato; Yusuke Shiozawa; Tetsuichi Yoshizato; Kenichi Yoshida; Hideki Makishima; Masako Iwanaga; Guangyong Ma; Kisato Nosaka; Masakatsu Hishizawa; Hidehiro Itonaga; Yoshitaka Imaizumi; Wataru Munakata; Hideaki Ogasawara; Toshitaka Sato; Ken Sasai; Kenzo Muramoto; Marina Penova; Takahisa Kawaguchi; Hiromi Nakamura; Natsuko Hama; Kotaro Shide; Yoko Kubuki; Tomonori Hidaka; Takuro Kameda; Tsuyoshi Nakamaki; Ken Ishiyama; Shuichi Miyawaki; Sung-Soo Yoon; Kensei Tobinai; Yasushi Miyazaki; Akifumi Takaori-Kondo; Fumihiko Matsuda; Kengo Takeuchi; Osamu Nureki; Hiroyuki Aburatani; Toshiki Watanabe; Tatsuhiro Shibata; Masao Matsuoka; Satoru Miyano; Kazuya Shimoda; Seishi Ogawa
Journal:  Nat Genet       Date:  2015-10-05       Impact factor: 38.330

3.  Precision glycocalyx editing as a strategy for cancer immunotherapy.

Authors:  Han Xiao; Elliot C Woods; Petar Vukojicic; Carolyn R Bertozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-22       Impact factor: 11.205

4.  High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival.

Authors:  Qingqing Wang; Qichao Ni; Xudong Wang; Huijun Zhu; Zhiwei Wang; Jianfei Huang
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

Review 5.  Synthetic immune niches for cancer immunotherapy.

Authors:  Jorieke Weiden; Jurjen Tel; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2017-08-30       Impact factor: 53.106

Review 6.  Versatile roles of extracellular vesicles in cancer.

Authors:  Nobuyoshi Kosaka; Yusuke Yoshioka; Yu Fujita; Takahiro Ochiya
Journal:  J Clin Invest       Date:  2016-03-14       Impact factor: 14.808

7.  Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer.

Authors:  Mengmeng Jiang; Wenwen Zhang; Rui Zhang; Pengpeng Liu; Yingnan Ye; Wenwen Yu; Xiaojing Guo; Jinpu Yu
Journal:  Oncogene       Date:  2020-05-12       Impact factor: 9.867

Review 8.  Emerging trends in the immunotherapy of pancreatic cancer.

Authors:  Kasturi Banerjee; Sushil Kumar; Kathleen A Ross; Shailendra Gautam; Brittany Poelaert; Mohd Wasim Nasser; Abhijit Aithal; Rakesh Bhatia; Michael J Wannemuehler; Balaji Narasimhan; Joyce C Solheim; Surinder K Batra; Maneesh Jain
Journal:  Cancer Lett       Date:  2017-12-12       Impact factor: 8.679

9.  CD47 is associated with the up-regulation of the PD-1 oncogenic signaling pathway.

Authors:  Danzhen Yao; Jinying Xia; Jianhui Li; Jun Xu
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

10.  High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia.

Authors:  Kongfei Li; Lieguang Chen; Hua Zhang; Lu Wang; Keya Sha; Xiaohong Du; Daiyang Li; Zhongzheng Zheng; Renzhi Pei; Ying Lu; Hongyan Tong
Journal:  Aging (Albany NY)       Date:  2021-04-23       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.